| INTRODUCTION
Treatment for Hodgkin lymphoma (HL) has evolved over the last 50 years from extended field radiotherapy to the use of multimodality regimens tailored to individual patients' disease characteristics, with the recent addition of antibody-drug conjugate therapies and immune checkpoint inhibitors. This progress has translated into 10-year survival rates above 80% with current standard treatment approaches, although long-term follow-up of these survivors shows that a minority experience significant morbidity and mortality as a result of their treatment, such as second malignancies and cardiovascular disease. 1 This has led to a more individualised approach to treatment, using risk-and response-adapted strategies, with the aim of de-escalating treatment and minimising toxicity without compromising survival in patients whose disease can be cured by less toxic regimens, while intensifying treatment in patients with high risk disease who stand to gain the most benefit. The general improvement in outcomes has not been matched in the older population, where there is as yet no standard treatment approach, and we lack clinical trial data to support decision making in patients more than the age of 60. to receive a further four cycles of either ABVD or AVD. 5 The omission of bleomycin in cycles 3 to 6 resulted in similar 3-year PFS and overall survival (OS) rates compared with those patients receiving a total of six cycles of ABVD, with reduced pulmonary toxicity (3-year PFS 84% versus 86% and OS 98% versus 97%, respectively). This led to the conclusion that bleomycin can be safely excluded from treatment in patients with early complete metabolic response. In the same trial, patients with a positive iPET were escalated to BEACOPP regimens, resulting in a 3-year PFS of 68%, which compared favourably to outcomes in studies in which patients continued with ABVD despite a positive iPET. The LYSA AHL2011 trial started with two cycles of the more intensive escBEACOPP regimen. Five-year PFS and OS rates did not significantly differ between patients treated with a standard approach, who received six cycles of escBEACOPP, compared with resulting in a 2-year PFS of 75%; similar to the 81% seen in patients who were iPET negative. 7 The early use of high-dose intensification in the small patient population genuinely refractory to primary chemotherapy may offer advantages for long-term disease control.
| RISK-AND RESPONSE-ADAPTED THERAPY
The omission of consolidation radiotherapy (RT), following a negative iPET in the RATHL trial, resulted in only 6.5% of patients overall receiving RT, without apparent loss of disease control. 5 SImilarly, the GHSG HD15 trial found that the omission of consolidation RT in patients with a negative iPET scan and residual masses of less than 2.5 cm did not compromise overall treatment efficacy. 8 This was confirmed in a randomised trial by the GITL/FIL group, who assigned patients with a large nodal mass at diagnosis (greater than 5 cm) to radiotherapy versus no further treatment in those with complete metabolic remission at iPET and the end of treatment. 9 There was no significant difference in 3-year PFS between the two groups (97% vs. 93% P = 0.29) leading to the conclusion that RT can be safely omitted in patients with a negative iPET, even if they present with bulky disease. The use of RT for patients with a persistent single site FDG-avid focus may avoid the need for more intensive chemotherapy regimes, but this approach has not been validated in prospective studies.
The treatment strategy for early stage disease has increasingly emphasised reducing long-term toxicity without compromising the excellent OS rates of over 95% at 10 years. Recent research has investigated the omission of radiotherapy for patients with a negative iPET. In the UK NCRI RAPID trial, patients with non-bulky Stage IA and IIA disease and a negative iPET defined as Deauville score 1 to 2, following three cycles of ABVD (75% of cases), were randomised to receive no further treatment or involved field radiotherapy. 10 There was a small but significant increase in recurrence rate in patients who did not receive radiotherapy, with a 3-year PFS of 94.6% in the radiotherapy group and 90.8% in the group who received only three ABVD, without a worsening of 3-year OS. A trial conducted by the EORTC, LYSA, and FIL groups (HD10) showed similar effects. In iPET-negative patients after two ABVD, the 5-year PFS rates in the favourable group who received either one ABVD plus Involved Node Radiotherapy or two further ABVD were 99.0% versus 87.1%, while in the unfavourable group who received either two ABVD plus INRT or four more ABVD, the 5-year PFS figures were closer, at 92.1% versus 89.6%. 11 The overall survival figures in both studies were very high, which argues for an individualised approach to treatment, balancing the small increase in the risk of recurrence against the potential morbidity of local radiotherapy. This will depend upon the particular sites of involvement and other factors such as gender and co-morbidity. For the future, the baseline evaluation of metabolic tumour volume and total lesional glycolysis may be helpful in estimating the risk from a radiation-free approach. 14 The use of BV combined with AVD in early stage unfavourable HL, followed by involved site radiotherapy (ISRT), did not appear to increase the rate of acute pulmonary toxicity while producing a high response rate in the Phase II study. 15 Patients received four cycles of BV + AVD with iPET following cycles 2 and 4. Treatment was not modified based on imaging, and 90% patients achieved a negative iPET (Deauville score 1-3)
after two cycles. The 1 year PFS was 93.3% and no patient had grade ≥ 3 pneumonitis. Whether radiotherapy could be omitted following this highly active regimen, given the high proportion of patients with a negative iPET, remains an open question, but it may be an attractive option for patients with bulky disease (defined as greater than 10 cm); 85% of whom achieved a negative iPET after only two cycles of treatment.
In the older population, BV may offer an alternative for patients unable to receive anthracyclines or bleomycin because of cardiorespiratory co-morbidity. It has been tested in combination with bendamustine or dacarbazine for patients with three or more co-morbidities unable to receive conventional regimens, 16 but there was a prohibitive rate of serious adverse events associated with BV plus bendamustine. By contrast, BV plus dacarbazine gave an overall response rate (ORR) of 100%
with complete responses in 62%, and a more favourable toxicity profile.
Sequential therapy with two cycles of BV followed by six cycles of AVD was investigated in a Phase II trial among 48 patients, with a median age of 67 and performance status of 1. 17 Patients whose disease responded to treatment received a further four cycles of BV monotherapy.
The 2-year PFS within the intention to treat population was 84%, with OS 93%, making this a potentially attractive option for fit older patients.
| CHECKPOINT BLOCKING ANTIBODIES
Cytogenetic studies have shown an amplification in copy number of the programmed cell death ligand (PDL1 and PDL2) gene loci in the majority of HL cases, leading to the up-regulation of PDL1 and PDL2 surface expression. 18 Nivolumab is an antiprogrammed cell death 
